Each ml contains:
Cisatracurium Besylate USP
Eq. to Cisatracurium 2mg
Benzyl Alcohol USP 0.9%
(As preservative in Multi dose Vial)
Water for Injection USP q.s.
Pharmacotherapeutic group: Neuromuscular blocking agent
ATC code: M03AC11
Cisatracurium is an intermediate-duration, non-depolarising benzylisoquinolinium skeletal
Clinical studies in man indicated that cisatracurium is not associated with dose dependent
histamine release even at doses up to and including 8 x ED95.
Mechanism of action
Cisatracurium binds to cholinergic receptors on the motor end-plate to antagonise the action of
acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is
readily reversed by anti-cholinesterase agents such as neostigmine or edrophonium.
The ED95 (dose required to produce 95% depression of the twitch response of the adductor
pollicis muscle to stimulation of the ulnar nerve) of cisatracurium is estimated to be 0.05 mg/kg
bodyweight during opioid anaesthesia (thiopentone/fentanyl/midazolam).
The ED95 of cisatracurium in children during halothane anaesthesia is 0.04 mg/kg.
Cisatracurium Besylate Injection USP 2mgml